Improving fecal sample collection in patients with inflammatory bowel disease: A comparative evaluation of two calprotectin devices - 08/08/25
, Amale Antari b , Damien Masson b , Thomas Dejoie b , Marie-Anne Vibet c , Michael Collins a , Hélène Caillon b , Arnaud Bourreille a , Catherine Le Berre a, ⁎ Highlights |
• | Sampling bottle improved stool collection acceptability versus standard container. |
• | High compliance rates were achieved with both collection methods in IBD patients. |
• | A long home-hospital distance was also associated with better acceptability. |
• | Patient-centric innovations can enhance IBD monitoring and diagnostic testing. |
Abstract |
Background |
Fecal calprotectin (FC) is a non-invasive biomarker that can be used to guide treatment decisions in inflammatory bowel diseases (IBD). Low compliance may hinder routine testing, with stool collection being the primary obstacle.
Aims |
The objective was to compare an alternative collection device (sampling bottle) to a conventional container for stool sampling in terms of acceptability and compliance with FC testing in patients with IBD.
Methods |
In this prospective study, patients were randomly assigned 1:1 to either the standard laboratory method (Bühlmann fCAL® turbo) or the ProciseFCP™ assay. Acceptability was assessed using qualitative and quantitative scales. Factors associated with FC acceptability, and compliance with FC testing, were analyzed. Only the stool sampling procedure was evaluated, not the satisfaction with the ‘point-of-care’ assay.
Results |
In total, 156 patients were included. The ProciseFCP™ device was associated with higher acceptability than the standard container on the ordinal scale (primary outcome) (OR 2.69, p < 0.001). Using the visual analog scale (secondary outcome), a positive difference of 30.0 % (95 % CI: 19.7 to 44.7) was found in favor of the ProciseFCP™ arm, but this was not statistically significant (CI including the predefined threshold of a 30-point difference). Compliance was similar and high in both groups (80 %).
Conclusion |
This study demonstrates that a sampling bottle offers a patient-friendly alternative to the conventional stool container, significantly enhancing patient’s acceptability with stool collection. These findings support the integration of patient-centric innovations in diagnostic testing to improve the monitoring and management of IBD.
Le texte complet de cet article est disponible en PDF.Keywords : Crohn’s disease, Ulcerative colitis, Biomarker, Compliance, Adherence
Plan
Vol 49 - N° 8
Article 102665- septembre 2025 Retour au numéro
Article précédent
- Evolving end-of-life care patterns for hepatocellular carcinoma in the United States: A 25-year national analysis of disparities in home and hospice utilization
- Mohamed Elnaggar, Ibrahim Hassan, Hatem Eltaly, Ayah Obeid, Raffi Karagozian
- A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy
- Anne Sophie Duquerois, Christine Martinez-Vinson, Thomas Loppinet, Lioara Restier, Pierre Poinsot, Aurélie Portefaix, Sophie Heissat, Noel Peretti, Nicolas Caron, Rémi Duclaux-Loras
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?